


## Supporting Information

### **2-deoxystreptamine as a platform to design original inhibitors of oncogenic miRNA biogenesis**


Thi Phuong Anh Tran, Nadia Patino, Audrey Di Giorgio, Maria Duca

Université Côte d'Azur, CNRS, Institut de Chimie de Nice (ICN), 28 avenue Valrose, 06100 Nice  
France


**Figure S1.** Chemical structures of the commercially available amines employed for the preparation of conjugates **3a-e** and *N*-(3-(1-(3-aminopropyl)-1*H*-imidazol-4-yl)phenyl)benzamide employed for the preparation of conjugate **3f**.




**Figure S2.** Commercially available isocyanates employed for the preparation of conjugates **3g-i**.



Butyl isocyanate




2,4-Dichloro-1-(2-isocyanatoethyl)benzene




1-Fluoro-4-(2-isocyanatoethyl)benzene

**Figure S3.** Dissociation constants ( $K_D$ ) curves for compounds **4b**, **4f**, **4h** and **4i** binding to pre-miR-372.



**Figure S4.** Molecular docking of compound **4f** performed on a pre-miR-17 structure using Autodock 4 software.



**Figure S5.**  $^1\text{H}$ ,  $^{13}\text{C}$  NMR and HRMS spectra of the most active compound **4f**.

